- Home
- LE vs KOD Comparison
LE vs KOD Comparison
Compare LE & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LE
- KOD
- Stock Information
- Founded
- LE 1963
- KOD 2009
- Country
- LE United States
- KOD United States
- Employees
- LE N/A
- KOD N/A
- Industry
- LE Clothing/Shoe/Accessory Stores
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LE Consumer Discretionary
- KOD Health Care
- Exchange
- LE Nasdaq
- KOD Nasdaq
- Market Cap
- LE 274.7M
- KOD 259.6M
- IPO Year
- LE N/A
- KOD 2018
- Fundamental
- Price
- LE $8.42
- KOD $3.40
- Analyst Decision
- LE Strong Buy
- KOD Hold
- Analyst Count
- LE 1
- KOD 3
- Target Price
- LE $20.00
- KOD $9.00
- AVG Volume (30 Days)
- LE 216.7K
- KOD 440.1K
- Earning Date
- LE 06-05-2025
- KOD 05-14-2025
- Dividend Yield
- LE N/A
- KOD N/A
- EPS Growth
- LE N/A
- KOD N/A
- EPS
- LE 0.20
- KOD N/A
- Revenue
- LE $1,362,935,000.00
- KOD N/A
- Revenue This Year
- LE $4.26
- KOD N/A
- Revenue Next Year
- LE $2.67
- KOD N/A
- P/E Ratio
- LE $42.16
- KOD N/A
- Revenue Growth
- LE N/A
- KOD N/A
- 52 Week Low
- LE $7.65
- KOD $1.92
- 52 Week High
- LE $19.88
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- LE 43.03
- KOD 45.30
- Support Level
- LE $8.52
- KOD $3.46
- Resistance Level
- LE $9.15
- KOD $3.81
- Average True Range (ATR)
- LE 0.39
- KOD 0.42
- MACD
- LE 0.01
- KOD -0.07
- Stochastic Oscillator
- LE 0.85
- KOD 34.50
About LE Lands' End Inc.
Lands' End Inc is a United States-based multi-channel retailer of casual clothing, accessories, and footwear, as well as home products. The company's operating segment includes U.S. eCommerce; International; Outfitters; Third Party and Retail. It generates maximum revenue from the U.S. eCommerce segment. The U.S. eCommerce segment offers products through the company's eCommerce website. Geographically, it derives a majority of its revenue from the United States.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.